ABSTRACT
A variety of disease- and treatment-related factors affect the coagulation system and the risk of bleeding and thrombotic complications in patients with multiple myeloma (MM) and related plasma cell disorders (PCD). As commonly observed in other cancer settings, the malignant clone induces a cytokine environment responsible for a hypercoagulable state. The increase of blood viscosity and impairment of platelet and coagulation function due to circulating monoclonal proteins are considered key mechanisms in the hemostatic abnormalities frequently detected in patients with PCD. However, clinically significant bleeding is relatively rare and poorly correlated with these abnormalities. Management is often challenging because of the multifactorial pathogenesis and underestimation or misdiagnosis of acquired bleeding disorders, particularly acquired von Willebrand syndrome. In recent years, growing interest in thromboembolic risk has emerged after the introduction of novel and more effective antimyeloma agents (thalidomide and lenalidomide), which was associated with increased risk of venous thromboembolism, particularly when associated with dexamethasone and multiagent chemotherapy in newly diagnosed patients. The clinical impact of bleeding and thrombotic complications in patients with PCD, with emphasis on MM, will be discussed in this review, reporting the current knowledge about pathophysiologic mechanisms and implications for management.
KEYWORDS
Bleeding - hypercoagulability - M protein - multiple myeloma - plasma cell disorders - prophylaxis - thrombosis
REFERENCES
-
1
Green D.
Management of bleeding complications of hematologic malignancies.
Semin Thromb Hemost.
2007;
33
(4)
427-434
-
2
Chong B H, Lee S-H.
Management of thromboembolism in hematologic malignancies.
Semin Thromb Hemost.
2007;
33
(4)
435-448
-
3
Franchini M, Dario Di Minno M N, Coppola A.
Disseminated intravascular coagulation in hematologic malignancies.
Semin Thromb Hemost.
2010;
36
(4)
388-403
-
4
Falanga A, Ofosu F A, Delaini F et al..
The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions.
Blood Coagul Fibrinolysis.
1994;
5
(Suppl 1)
S19-S23, discussion 59–64
-
5
Falanga A, Rickles F R.
Pathophysiology of the thrombophilic state in the cancer patient.
Semin Thromb Hemost.
1999;
25
(2)
173-182
-
6
Zangari M, Elice F, Fink L, Tricot G.
Hemostatic dysfunction in paraproteinemias and amyloidosis.
Semin Thromb Hemost.
2007;
33
(4)
339-349
-
7
Eby C.
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
Br J Haematol.
2009;
145
(2)
151-163
-
8
Zangari M, Anaissie E, Barlogie B et al..
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Blood.
2001;
98
(5)
1614-1615
-
9
Kyle R A, Gertz M A, Witzig T E et al..
Review of 1027 patients with newly diagnosed multiple myeloma.
Mayo Clin Proc.
2003;
78
(1)
21-33
-
10
Kumar S K, Rajkumar S V, Dispenzieri A et al..
Improved survival in multiple myeloma and the impact of novel therapies.
Blood.
2008;
111
(5)
2516-2520
-
11
Uaprasert N, Voorhees P M, Mackman N, Key N S.
Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Eur J Cancer.
2010;
46
(10)
1790-1799
-
12
Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M.
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Semin Thromb Hemost.
2011;
37
(3)
209-219
-
13
Rajkumar S V, Dispenzieri A, Kyle R A.
Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.
Mayo Clin Proc.
2006;
81
(5)
693-703
-
14
Kristinsson S Y, Fears T R, Gridley G et al..
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.
Blood.
2008;
112
(9)
3582-3586
-
15
Kyle R A, Rajkumar S V.
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.
Leukemia.
2009;
23
(1)
3-9
-
16
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J.
Cancer statistics, 2009.
CA Cancer J Clin.
2009;
59
(4)
225-249
-
17
Perkins H A, MacKenzie M R, Fudenberg H H.
Hemostatic defects in dysproteinemias.
Blood.
1970;
35
(5)
695-707
-
18
Niléhn J E, Nilsson I M.
Coagulation studies in different types of myeloma.
Acta Med Scand Suppl.
1966;
445
194-199
-
19
Penny R, Castaldi P A, Whitsed H M.
Inflammation and haemostasis in paraproteinaemias.
Br J Haematol.
1971;
20
(1)
35-44
-
20
Mehta J, Singhal S.
Hyperviscosity syndrome in plasma cell dyscrasias.
Semin Thromb Hemost.
2003;
29
(5)
467-471
-
21
Kwaan H C, Bongu A.
The hyperviscosity syndromes.
Semin Thromb Hemost.
1999;
25
(2)
199-208
-
22
Crawford J, Cox E B, Cohen H J.
Evaluation of hyperviscosity in monoclonal gammopathies.
Am J Med.
1985;
79
(1)
13-22
-
23
Sucker C, Hetzel G R, Grabensee B, Stockschlaeder M, Scharf R E.
Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy.
Am J Kidney Dis.
2006;
47
(6)
947-955
-
24
Kyle R A.
Multiple myeloma: review of 869 cases.
Mayo Clin Proc.
1975;
50
(1)
29-40
-
25
Rossi D, De Paoli L, Franceschetti S et al..
Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance.
Br J Haematol.
2007;
138
(2)
249-252
-
26
Alpay N, Uzun S, Bahat G, Yavuz S, Erten N, Tascioglu C.
Thrombotic thrombocytopenic purpura associated with multiple myeloma.
Blood Coagul Fibrinolysis.
2008;
19
(5)
439-441
-
27
Hofmeister C C, Jin M, Cataland S R, Benson D M, Wu H M.
TTP disease course is independent of myeloma treatment and response.
Am J Hematol.
2010;
85
(4)
304-306
-
28
Sharma P, Kar R, Bhargava R, Ranjan R, Mishra PC, Saxena R.
Acquired platelet dysfunction in 109 patients from a tertiary care referral hospital.
Clin Appl Thromb Hemost.
2011;
17
(1)
88-93
-
29
DiMinno G, Coraggio F, Cerbone A M et al..
A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder.
J Clin Invest.
1986;
77
(1)
157-164
-
30
Ingram G I, Kingston P J, Leslie J, Bowie E J.
Four cases of acquired von Willebrand's syndrome.
Br J Haematol.
1971;
21
(2)
189-199
-
31
Handin R I, Martin V, Moloney W C.
Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome.
Blood.
1976;
48
(3)
393-405
-
32
Federici A B, Budde U, Rand J H.
Acquired von Willebrand syndrome 2004: International Registry—diagnosis and management from online to bedside.
Hamostaseologie.
2004;
24
(1)
50-55
-
33
Franchini M, Lippi G.
Acquired von Willebrand syndrome: an update.
Am J Hematol.
2007;
82
(5)
368-375
-
34
Tiede A, Priesack J, Werwitzke S et al..
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.
J Thromb Haemost.
2008;
6
(4)
569-576
-
35
Federici A B.
Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders.
Semin Hematol.
2006;
43
(1, Suppl 1)
S48-S58
-
36
Federici A B.
Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?.
J Thromb Haemost.
2008;
6
(4)
565-568
-
37 International Registry on Acquired von Willebrand Syndrome .Available at http://www.intreavws.com Accessed on January 21, 2011
-
38
Michiels J J, Budde U, van der Planken M, van Vliet H H, Schroyens W, Berneman Z.
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Best Pract Res Clin Haematol.
2001;
14
(2)
401-436
-
39
Scrobohaci M L, Daniel M T, Levy Y, Marolleau J P, Brouet J C.
Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease.
Br J Haematol.
1993;
84
(3)
471-475
-
40
Eikenboom J C, van der Meer F J, Briët E.
Acquired von Willebrand's disease due to excessive fibrinolysis.
Br J Haematol.
1992;
81
(4)
618-620
-
41
Shinagawa A, Kojima H, Berndt M C et al..
Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
Thromb Haemost.
2005;
93
(5)
889-896
-
42
van Genderen P J, Vink T, Michiels J J, van 't Veer M B, Sixma J J, van Vliet H H.
Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
Blood.
1994;
84
(10)
3378-3384
-
43
Siaka C, Rugeri L, Caron C, Goudemand J.
A new ELISA assay for diagnosis of acquired von Willebrand syndrome.
Haemophilia.
2003;
9
(3)
303-308
-
44
Coleman R, Favaloro E J, Soltani S, Keng T B.
Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor.
J Thromb Haemost.
2006;
4
(9)
2085-2088
-
45
Guerin V, Ryman A, Velez F.
Acquired von Willebrand disease: potential contribution of the von Willebrand factor collagen-binding to the identification of functionally inhibiting auto-antibodies to von Willebrand factor: a rebuttal.
J Thromb Haemost.
2008;
6
(6)
1051-1052
-
46
Mohri H, Motomura S, Kanamori H et al..
Clinical significance of inhibitors in acquired von Willebrand syndrome.
Blood.
1998;
91
(10)
3623-3629
-
47
Teng H W, Chen P M, Yang Y H, Gau J P.
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Jpn J Clin Oncol.
2007;
37
(8)
609-614
-
48
O'Kane M J, Wisdom G B, Desai Z R, Archbold G P.
Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin.
J Clin Pathol.
1994;
47
(3)
266-268
-
49
Kotlín R, Sobotková A, Riedel T et al..
Acquired dysfibrinogenemia secondary to multiple myeloma.
Acta Haematol.
2008;
120
(2)
75-81
-
50
Glueck H I, Hong R.
A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin.
J Clin Invest.
1965;
44
(11)
1866-1881
-
51
Sallah S, Nguyen N P, Abdallah J M, Hanrahan L R.
Acquired hemophilia in patients with hematologic malignancies.
Arch Pathol Lab Med.
2000;
124
(5)
730-734
-
52
Franchini M, Targher G, Manzato F, Lippi G.
Acquired factor VIII inhibitors in oncohematology: a systematic review.
Crit Rev Oncol Hematol.
2008;
66
(3)
194-199
-
53
Sari I, Erkurt M A, Ifran A, Kaptan K, Beyan C.
Multiple myeloma presenting with acquired factor VIII inhibitor.
Int J Hematol.
2009;
90
(2)
166-169
-
54
Colwell N S, Tollefsen D M, Blinder M A.
Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.
Br J Haematol.
1997;
97
(1)
219-226
-
55
Holme P A, Brosstad F, Tjønnfjord G E.
Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
Haemophilia.
2005;
11
(5)
510-515
-
56
Llamas P, Outeiriño J, Espinoza J, Santos A B, Román A, Tomás J F.
Report of three cases of circulating heparin-like anticoagulants.
Am J Hematol.
2001;
67
(4)
256-258
-
57
Palmer R N, Rick M E, Rick P D, Zeller J A, Gralnick H R.
Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder.
N Engl J Med.
1984;
310
(26)
1696-1699
-
58
Goddard I R, Stewart W K, Hodson B A, Dawes J.
Plasma exchange as a treatment for endogenous glycosaminoglycan anticoagulant induced haemorrhage in a patient with myeloma kidney.
Nephron.
1990;
56
(1)
94-96
-
59
Torjemane L, Guermazi S, Ladeb S et al..
Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate.
Blood Coagul Fibrinolysis.
2007;
18
(3)
279-281
-
60
Yood R A, Skinner M, Rubinow A, Talarico L, Cohen A S.
Bleeding manifestations in 100 patients with amyloidosis.
JAMA.
1983;
249
(10)
1322-1324
-
61
Gastineau D A, Gertz M A, Daniels T M, Kyle R A, Bowie E J.
Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality.
Blood.
1991;
77
(12)
2637-2640
-
62
Gamba G, Montani N, Anesi E et al..
Clotting alterations in primary systemic amyloidosis.
Haematologica.
2000;
85
(3)
289-292
-
63
Mumford A D, O'Donnell J, Gillmore J D, Manning R A, Hawkins P N, Laffan M.
Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.
Br J Haematol.
2000;
110
(2)
454-460
-
64
Greipp P R, Kyle R A, Bowie E J.
Factor-X deficiency in amyloidosis: a critical review.
Am J Hematol.
1981;
11
(4)
443-450
-
65
Furie B, Greene E, Furie B C.
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
N Engl J Med.
1977;
297
(2)
81-85
-
66
Sane D C, Pizzo S V, Greenberg C S.
Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review.
Am J Hematol.
1989;
31
(1)
53-57
-
67
Liebman H A, Carfagno M K, Weitz I C et al..
Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase.
Am J Clin Pathol.
1992;
98
(5)
534-541
-
68
Bouma B, Maas C, Hazenberg B P, Lokhorst H M, Gebbink M F.
Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses.
J Thromb Haemost.
2007;
5
(6)
1139-1142
-
69
Rodrigues C A, Ferrarotto R, Kalil Filho R, Novis YAS, Hoff PMG.
Venous thromboembolism and cancer: a systematic review.
J Thromb Thrombolysis.
2010;
30
(1)
67-78
-
70
Goldhaber S Z.
Risk factors for venous thromboembolism.
J Am Coll Cardiol.
2010;
56
(1)
1-7
-
71
Bennet C L, Angelotta C, Yarnold P R et al..
Thalidomide- and lenalinomide-associated thromboembolism among patients with cancer.
JAMA.
2006;
296
(21)
2558-2560
-
72
Bennett C L, Silver S M, Djulbegovic B et al..
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
JAMA.
2008;
299
(8)
914-924
-
73
Katodritou E, Verrou E, Hadjiaggelidou C et al..
Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
Am J Hematol.
2008;
83
(9)
697-701
-
74
Bohlius J, Schmidlin K, Brillant C et al..
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
Lancet.
2009;
373
(9674)
1532-1542
-
75
Srkalovic G, Cameron M G, Rybicki L, Deitcher S R, Kattke-Marchant K, Hussein M A.
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Cancer.
2004;
101
(3)
558-566
-
76
Sallah S, Husain A, Wan J, Vos P, Nguyen N P.
The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance.
Ann Oncol.
2004;
15
(10)
1490-1494
-
77
Petropoulou A D, Gerotziafas G T, Samama M M, Hatmi M, Rendu F, Elalamy I.
In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide.
Thromb Res.
2008;
121
(4)
493-497
-
78
Carr Jr M E, Dent R M, Carr S L.
Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma.
J Lab Clin Med.
1996;
128
(1)
83-88
-
79
Yağci M, Sucak G T, Haznedar R.
Fibrinolytic activity in multiple myeloma.
Am J Hematol.
2003;
74
(4)
231-237
-
80
Tricot G.
New insights into role of microenvironment in multiple myeloma.
Lancet.
2000;
355
(9200)
248-250
-
81
Barillé S, Bataille R, Amiot M.
The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
Eur Cytokine Netw.
2000;
11
(4)
546-551
-
82
Mechtcheriakova D, Wlachos A, Holzmüller H, Binder B R, Hofer E.
Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1.
Blood.
1999;
93
(11)
3811-3823
-
83
Amrani D L.
Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control.
Blood Coagul Fibrinolysis.
1990;
1
(4–5)
443-446
-
84
Stirling D, Hannant W A, Ludlam C A.
Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6.
Thromb Haemost.
1998;
79
(1)
74-78
-
85
Auwerda JJA, Sonneveld P, de Maat MPM, Leebeek FWG.
Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.
Haematologica.
2007;
92
(2)
279-280
-
86
van Marion AMW, Auwerda JJA, Lisman T et al..
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
Leuk Res.
2008;
32
(7)
1078-1084
-
87
Zangari M, Saghafifar F, Anaissie E et al..
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Blood Coagul Fibrinolysis.
2002;
13
(3)
187-192
-
88
Elice F, Fink L, Tricot G, Barlogie B, Zangari M.
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
Br J Haematol.
2006;
134
(4)
399-405
-
89
Gruber A, Blaskó G, Sas G.
Functional deficiency of protein C and skin necrosis in multiple myeloma.
Thromb Res.
1986;
42
(4)
579-581
-
90
Deitcher S R, Erban J K, Limentani S A.
Acquired free protein S deficiency associated with multiple myeloma: a case report.
Am J Hematol.
1996;
51
(4)
319-323
-
91
Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J.
Light-chain paraproteins with lupus anticoagulant activity.
Am J Hematol.
1999;
62
(2)
99-102
-
92
Bellotti V, Gamba G, Merlini G et al..
Study of three patients with monoclonal gammopathies and ‘lupus-like’ anticoagulants.
Br J Haematol.
1989;
73
(2)
221-227
-
93
Takamiya O, Machida S, Okuda M, Nojima J, Koreeda C, Kubara K.
A non-immunological phospholipid-dependent coagulation inhibitor associated with IgGlambda-type multiple myeloma.
Am J Hematol.
2004;
75
(1)
34-39
-
94
Swystun L L, Shin L Y, Beaudin S, Liaw P C.
Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes.
J Thromb Haemost.
2009;
7
(4)
619-626
-
95
Reddy K V, Bhattacharjee G, Schabbauer G et al..
Dexamethasone enhances LPS induction of tissue factor expression in human monocytic cells by increasing tissue factor mRNA stability.
J Leukoc Biol.
2004;
76
(1)
145-151
-
96
Kerachian M A, Cournoyer D, Harvey E J et al..
Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion.
J Steroid Biochem Mol Biol.
2009;
116
(3–5)
127-133
-
97
van Giezen J J, Jansen J W.
Correlation of in vitro and in vivo decreased fibrinolytic activity caused by dexamethasone.
Ann N Y Acad Sci.
1992;
667
199-201
-
98
Arkel Y S, Ku D H, Thurston A L.
The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)-alpha-stimulated cells.
J Thromb Haemost.
2003;
1
(12)
2691-2692
-
99
Zangari M, Guerrero J, Cavallo F, Prasad H K, Esseltine D, Fink L.
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Haematologica.
2008;
93
(6)
953-954
-
100
Hiroi T, Deming C B, Zhao H et al..
Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.
Arterioscler Thromb Vasc Biol.
2009;
29
(10)
1587-1593
-
101
Ghosh N, Ye X, Ferguson A, Huff C A, Borrello I.
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Br J Haematol.
2011;
152
(5)
593-599
-
102
Lackner H.
Hemostatic abnormalities associated with dysproteinemias.
Semin Hematol.
1973;
10
(2)
125-133
-
103
Glaspy J A.
Hemostatic abnormalities in multiple myeloma and related disorders.
Hematol Oncol Clin North Am.
1992;
6
(6)
1301-1314
-
104
Talamo G, Farooq U, Zangari M et al..
Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma.
Clin Lymphoma Myeloma Leuk.
2010;
10
(6)
464-468
-
105
Kyrtsonis M C, Vassilakopoulos T P, Angelopoulou M K et al..
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Ann Hematol.
2001;
80
(12)
722-727
-
106
Kyle R A, Gertz M A.
Primary systemic amyloidosis: clinical and laboratory features in 474 cases.
Semin Hematol.
1995;
32
(1)
45-59
-
107
Ebert E C, Nagar M.
Gastrointestinal manifestations of amyloidosis.
Am J Gastroenterol.
2008;
103
(3)
776-787
-
108
Kim S H, Kang E J, Park J W et al..
Gastrointestinal amyloidosis presenting with multiple episodes of gastrointestinal bleeding.
Cardiovasc Intervent Radiol.
2009;
32
(3)
577-580
-
109
Oluk M A, Murphy J.
Nasopharyngeal amyloidosis: an unusual cause for epistaxis.
J Laryngol Otol.
2010;
124
(2)
209-212
-
110
Morita Y, Yasuda M, Nakao M, Tsujimura Y, Isono M.
Pulmonary hemorrhage and acute renal failure as an initial presentation of multiple myeloma.
Intern Med.
2010;
49
(14)
1401-1403
-
111
Crowley R W, Sansur C A, Sheehan J P, Mandell J W, Kassell N F, Dumont A S.
Intracranial plasmacytoma with apoplectic presentation and spontaneous intracerebral hemorrhage: Case report and review of the literature.
Clin Neurol Neurosurg.
2010;
112
(2)
172-175
-
112
Oshima K, Kanda Y, Nannya Y et al..
Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma.
Am J Hematol.
2001;
67
(1)
1-5
-
113
Franchini M, Lippi G.
Acquired factor VIII inhibitors.
Blood.
2008;
112
(2)
250-255
-
114
Collins P, Budde U, Rand J H, Federici A B, Kessler C M.
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome.
Haemophilia.
2008;
14
(Suppl 3)
49-55
-
115
Franchini M.
The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.
Blood Transfus.
2009;
7
(1)
24-28
-
116
De Simone C, Catalano L, Coppola A et al..
Acquired hemophilia: an early marker of relapse in a patient with a history of multiple myeloma.
Haematologica.
2004;
89
(Suppl 8)
145
-
117
Boggio L, Green D.
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Br J Haematol.
2001;
112
(4)
1074-1075
-
118
Mannucci P M, Levi M.
Prevention and treatment of major blood loss.
N Engl J Med.
2007;
356
(22)
2301-2311
-
119
Friederich P W, Wever P C, Briët E, Doorenbos C J, Levi M.
Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease.
Am J Hematol.
2001;
66
(4)
292-294
-
120
Smaradottir A, Bona R.
A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy.
Thromb Haemost.
2004;
92
(5)
666-667
Correction in Thromb Haemost 2005; 93(5):1009
-
121
Federici A B, Stabile F, Castaman G, Canciani M T, Mannucci P M.
Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.
Blood.
1998;
92
(8)
2707-2711
-
122
Thompson C A, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A.
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Am J Hematol.
2010;
85
(3)
171-173
-
123
Zangari M, Tricot G, Polavaram L et al..
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
J Clin Oncol.
2010;
28
(1)
132-135
-
124
Carrier M, Le Gal G, Tay J, Wu C, Lee A Y.
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
J Thromb Haemost.
2011;
9
(4)
653-663
-
125
Verheul HMW, Pinedo H M.
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition.
Nat Rev Cancer.
2007;
7
(6)
475-485
-
126
Jagannath S, Barlogie B, Berenson J R SUMMIT/CREST Investigators et al.
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer.
2005;
103
(6)
1195-1200
-
127
Raven W, Berghout A, van Houten A, Leebeek F W.
Treatment of multiple myeloma and arterial thrombosis.
Ann Hematol.
2010;
89
(4)
419-420
-
128
Libourel E J, Sonneveld P, van der Holt B, de Maat MPM, Leebeek FWG.
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
Blood.
2010;
116
(1)
22-26
-
129
Geerts W H, Bergqvist D, Pineo G F American College of Chest Physicians et al.
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008;
133
(6, Suppl)
381S-453S
-
130
Palumbo A, Rajkumar S V, Dimopoulos M A International Myeloma Working Group et al.
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Leukemia.
2008;
22
(2)
414-423
-
131
Musallam K M, Dahdaleh F S, Shamseddine A I, Taher A T.
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Thromb Res.
2009;
123
(5)
679-686
-
132
Palumbo A, Davies F, Kropff M et al..
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
Ann Hematol.
2010;
89
(8)
803-811
-
133
Barlogie B, Tricot G, Anaissie E et al..
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
N Engl J Med.
2006;
354
(10)
1021-1030
-
134
Zangari M, Barlogie B, Anaissie E et al..
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Br J Haematol.
2004;
126
(5)
715-721
-
135
Palumbo A, Bringhen S, Caravita T Italian Multiple Myeloma Network, GIMEMA et al.
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Lancet.
2006;
367
(9513)
825-831
-
136
Minnema M C, Breitkreutz I, Auwerda J J et al..
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Leukemia.
2004;
18
(12)
2044-2046
-
137
Wang M, Weber D M, Delasalle K, Alexanian R.
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Am J Hematol.
2005;
79
(3)
194-197
-
138
Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R.
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
J Clin Oncol.
2003;
21
(1)
16-19
-
139
Cavo M, Zamagni E, Tosi P Bologna 2002 study et al.
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
Blood.
2005;
106
(1)
35-39
-
140
Klein U, Kosely F, Hillengass J et al..
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Ann Hematol.
2009;
88
(1)
67-71
-
141
Knop S, Gerecke C, Liebisch P et al..
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Blood.
2009;
113
(18)
4137-4143
-
142
Baz R, Li L, Kottke-Marchant K et al..
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
Mayo Clin Proc.
2005;
80
(12)
1568-1574
-
143
Rajkumar S V, Hayman S R, Lacy M Q et al..
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Blood.
2005;
106
(13)
4050-4053
-
144
Palumbo A, Falco P, Corradini P GIMEMA–Italian Multiple Myeloma Network et al.
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network.
J Clin Oncol.
2007;
25
(28)
4459-4465
Antonio CoppolaM.D.
Regional Reference Center for Coagulation Disorders
Federico II University Hospital, Via S. Pansini, 5 - Naples, Italy
Email: antocopp@unina.it
